CTOs on the Move

Innocrin Pharmaceuticals

www.innocrinpharma.com

 
Innocrin discovers and develops novel, best-in-class oral inhibitors of CYP17 lyase, a validated enzyme target for the treatment of castration-resistant prostate cancer (CRPC). VT-464 and structurally-related classes of CYP17 inhibitors are wholly owned by Innocrin. CYP17 lyase inhibitors may also have high commercial potential for the treatment of breast cancer as well as non-oncologic syndromes that are due to hormonal excess including endometriosis, polycystic ovary syndrome and congenital adrenal hyperplasia.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Similar Companies

Corden Pharma Colorado

Corden Pharma Colorado is a Boulder, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Alliance Health Networks

Alliance Health Networks is a Salt Lake City, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cephazone Pharma

Cephazone Pharma is a Pomona, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Valeant Pharmaceuticals

Valeant Pharmaceuticals International, Inc. is a diverse and decentralized pharmaceutical company that is committed to focusing on our key stakeholders while delivering consistently high performance. Our values provide the overall direction for our company, and provide us with the tools necessary to rise to any challenge by leveraging our collective hard work and effort along with our unwavering competitive spirit. These values help us set goals based on our organization’s potential and what we hope it will become.

Novis Pharmaceuticals

Novis Pharmaceuticals is a Miami, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.